Thirdly, although we investigated the effects of conditional knockdown of hepatic PCSK9 on HFD-induced liver inflammation following 3-month intervention and the underlying mechanisms of action, this study cannot reflect the potential different effects of PCSK9 in the dynamic processes of hyperlipidemia-induced liver inflammation. The gene discussed is PCSK9; the disease is hyperlipidemia.